16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine

C142H167N23O — CID 161062246

IUPAC16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine
SMILESCc1ccc(-c2ccc3c(c2)nc2n3CCCN3CCCCC3C2)cc1.c1cc2c(cc1CN1CCOCC1)nc1n2CCCN2CCCCC2C1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCCC4C3)cn2c1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCC[C@@H]4C3)cn2c1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCC[C@H]4C3)cn2c1.c1ccc2c(c1)CCN(Cc1ccc3c(c1)nc1n3CCCN3CCCCC3C1)C2
InChIInChI=1S/C26H32N4.3C24H26N4.C23H27N3.C21H30N4O/c1-2-7-22-19-28(15-11-21(22)6-1)18-20-9-10-25-24(16-20)27-26-17-23-8-3-4-12-29(23)13-5-14-30(25)26;3*1-2-11-26-13-4-14-28-23-10-8-18(15-22(23)25-24(28)16-21(26)5-1)19-7-9-20-6-3-12-27(20)17-19;1-17-6-8-18(9-7-17)19-10-11-22-21(15-19)24-23-16-20-5-2-3-12-25(20)13-4-14-26(22)23;1-2-7-24-8-3-9-25-20-6-5-17(16-23-10-12-26-13-11-23)14-19(20)22-21(25)15-18(24)4-1/h1-2,6-7,9-10,16,23H,3-5,8,11-15,17-19H2;3*3,6-10,12,15,17,21H,1-2,4-5,11,13-14,16H2;6-11,15,20H,2-5,12-14,16H2,1H3;5-6,14,18H,1-4,7-13,15-16H2/t;2*21-;;;/m.10.../s1
InChIKeyUDNZHHJZNJMWIJ-SJNQVXKNSA-N
MW2212.06 g/mol
LogP26.15
Rot. Bonds8

About 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine

16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine (PubChem CID 161062246) has the molecular formula C142H167N23O and a molecular weight of 2212.06 g/mol. Its IUPAC name is 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine.

Molecular Properties

Compound Name16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine
PubChem CID161062246
Molecular FormulaC142H167N23O
Molecular Weight2212.06 g/mol
Exact Mass2210.37
IUPAC Name16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine
SMILESCc1ccc(-c2ccc3c(c2)nc2n3CCCN3CCCCC3C2)cc1.c1cc2c(cc1CN1CCOCC1)nc1n2CCCN2CCCCC2C1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCCC4C3)cn2c1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCC[C@@H]4C3)cn2c1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCC[C@H]4C3)cn2c1.c1ccc2c(c1)CCN(Cc1ccc3c(c1)nc1n3CCCN3CCCCC3C1)C2
InChIInChI=1S/C26H32N4.3C24H26N4.C23H27N3.C21H30N4O/c1-2-7-22-19-28(15-11-21(22)6-1)18-20-9-10-25-24(16-20)27-26-17-23-8-3-4-12-29(23)13-5-14-30(25)26;3*1-2-11-26-13-4-14-28-23-10-8-18(15-22(23)25-24(28)16-21(26)5-1)19-7-9-20-6-3-12-27(20)17-19;1-17-6-8-18(9-7-17)19-10-11-22-21(15-19)24-23-16-20-5-2-3-12-25(20)13-4-14-26(22)23;1-2-7-24-8-3-9-25-20-6-5-17(16-23-10-12-26-13-11-23)14-19(20)22-21(25)15-18(24)4-1/h1-2,6-7,9-10,16,23H,3-5,8,11-15,17-19H2;3*3,6-10,12,15,17,21H,1-2,4-5,11,13-14,16H2;6-11,15,20H,2-5,12-14,16H2,1H3;5-6,14,18H,1-4,7-13,15-16H2/t;2*21-;;;/m.10.../s1
InChIKeyUDNZHHJZNJMWIJ-SJNQVXKNSA-N
XLogP26.15
TPSA155.30 Ų
H-Bond Donors
H-Bond Acceptors24
Rotatable Bonds8
Heavy Atoms166
Complexity—

Lipinski Rule of Five

3 violations

RuleValue
MW ≤ 5002212.06
LogP ≤ 526.15
H-Bond Donors ≤ 50
H-Bond Acceptors ≤ 1024

Analyze 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Related Compounds

3-cyclobutyl-10-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-2,4,5,6-tetrahydro-1H-[1,5]diazocino[1,2-a]benzimidazole
CID 51002040
15-methyl-8,11,18-triazatetracyclo[9.7.0.03,8.012,17]octadeca-1(18),12(17),13,15-tetraene
CID 58189332
2-cyclobutyl-8-(piperidin-1-ylmethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazole
CID 58189345
3-cyclohexyl-8-(4-methylphenyl)-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]benzimidazole;methane;3-(4-methylcyclohexyl)-8-(4-methylphenyl)-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]benzimidazole
CID 159656599
3-cyclobutyl-8-phenyl-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]benzimidazole
CID 58063789
3-cyclobutyl-N-[(4-methylphenyl)methyl]-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]benzimidazol-8-amine
CID 58063772
4-[2-(7-methyl-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]morpholine
CID 59017452
2-[(4-methylphenyl)methyl]-3,4,5,7,8,9,10,10a-octahydro-1H-pyrido[1,2-a][1,4]diazepine
CID 79926733
4-[[4-(8-methylimidazo[1,2-a]pyridin-2-yl)phenyl]methyl]morpholine
CID 58208395
3-cyclobutyl-8-pyridin-2-yl-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]benzimidazole
CID 56644753
N-[4-(3-cyclobutyl-1,2,4,5-tetrahydro-[1,4]diazepino[1,7-a]benzimidazol-8-yl)phenyl]acetamide
CID 58064005
7-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-4-[(1,3-dimethylpyrazol-4-yl)methyl]-3,5-dihydro-2H-1,4-benzoxazepine
CID 126466806

Frequently Asked Questions

What is the IUPAC name of 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine?
The IUPAC name of 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine (CID 161062246) is 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine.
What is the SMILES notation for 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine?
The canonical SMILES for 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine is Cc1ccc(-c2ccc3c(c2)nc2n3CCCN3CCCCC3C2)cc1.c1cc2c(cc1CN1CCOCC1)nc1n2CCCN2CCCCC2C1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCCC4C3)cn2c1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCC[C@@H]4C3)cn2c1.c1cc2ccc(-c3ccc4c(c3)nc3n4CCCN4CCCC[C@H]4C3)cn2c1.c1ccc2c(c1)CCN(Cc1ccc3c(c1)nc1n3CCCN3CCCCC3C1)C2.
What is the InChIKey of 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine?
The InChIKey is UDNZHHJZNJMWIJ-SJNQVXKNSA-N. The full InChI is InChI=1S/C26H32N4.3C24H26N4.C23H27N3.C21H30N4O/c1-2-7-22-19-28(15-11-21(22)6-1)18-20-9-10-25-24(16-20)27-26-17-23-8-3-4-12-29(23)13-5-14-30(25)26;3*1-2-11-26-13-4-14-28-23-10-8-18(15-22(23)25-24(28)16-21(26)5-1)19-7-9-20-6-3-12-27(20)17-19;1-17-6-8-18(9-7-17)19-10-11-22-21(15-19)24-23-16-20-5-2-3-12-25(20)13-4-14-26(22)23;1-2-7-24-8-3-9-25-20-6-5-17(16-23-10-12-26-13-11-23)14-19(20)22-21(25)15-18(24)4-1/h1-2,6-7,9-10,16,23H,3-5,8,11-15,17-19H2;3*3,6-10,12,15,17,21H,1-2,4-5,11,13-14,16H2;6-11,15,20H,2-5,12-14,16H2,1H3;5-6,14,18H,1-4,7-13,15-16H2/t;2*21-;;;/m.10.../s1.
What are the key properties of 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine?
16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine has a molecular weight of 2212.06 g/mol, XLogP of 26.15, 8 rotatable bonds, 0 hydrogen bond donors, and 24 hydrogen bond acceptors.
Where does this data come from?
All data for 16-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3S)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;(3R)-16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-indolizin-6-yl-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;16-(4-methylphenyl)-8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraene;4-(8,12,19-triazatetracyclo[10.7.0.03,8.013,18]nonadeca-1(19),13(18),14,16-tetraen-16-ylmethyl)morpholine is sourced from PubChem (CID 161062246), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).